bioMérieux acquires SpinChip to advance rapid diagnostics

FRANCE – Global diagnostics company bioMérieux has acquired SpinChip Diagnostics ASA, a Norwegian firm known for its groundbreaking immunoassay platform.

The small, benchtop analyzer developed by SpinChip can deliver lab-quality results from whole blood samples in under 10 minutes, making it ideal for near-patient testing.

This innovation aims to improve acute care, particularly in diagnosing myocardial infarction (MI), a leading cause of death worldwide.

SpinChip’s rapid testing platform has the potential to transform emergency care by reducing delays in diagnosis, which are often caused by the need to transport and process samples in centralized labs.

Current diagnostic methods, while accurate, are time-consuming, leading to longer hospital stays and higher costs.

Dr. Charles K. Cooper, chief medical officer at bioMérieux, praised the platform, saying, “The SpinChip solution is a game changer, combining the ease of use and fast time-to-result of point-of-care systems with the precision of high-sensitivity lab assays.

Allowing physicians to make an accurate and rapid diagnosis is crucial for patients with myocardial infarctions.”

Initially, SpinChip is focusing on well-established cardiac markers, such as high-sensitivity troponin I (hs-TnI), NT-proBNP, and D-Dimer.

These tests are critical for acute care settings, especially for heart-related emergencies. The performance of its first test, hs-TnI, has already been validated in a clinical study and is undergoing further assessment in a multicenter European trial.

SpinChip plans to apply for CE marking under the new In Vitro Diagnostic Regulation (IVDR) by the end of 2025. Future developments will expand the platform to cover other acute care needs.

Morten Jurs, CEO of SpinChip, expressed optimism about the acquisition, saying, “Over the past 10 years, SpinChip has developed a game-changing immunoassay POC platform to improve patient outcomes and reduce healthcare costs. Under bioMérieux’s ownership, our platform can reach the market and, most importantly, the patients.”

This acquisition aligns with bioMérieux’s strategic goals under its GO•28 plan, which focuses on strengthening the company’s position in point-of-care diagnostics.

Pierre Boulud, CEO of bioMérieux, explained, “SpinChip’s disruptive technology complements our existing BIOFIRE SPOTFIRE system and expands our capabilities in immunoassays. This acquisition will pave the way for bioMérieux’s growth beyond 2028, sustaining our mission to improve patient outcomes worldwide.”